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Leo J. Schouten, MDd Oss, Amsterdam, Arnhem, and Nijmegen, The Netherlands
Background: Few data are available on the accuracy of visual skin examination by derma­
tologists as a skin cancer and melanoma screening tool
Objective; The purpose of this study was to assess the number of false-negative findings in 
a skin can cer-m elan oma screening program.
Methods: We obtained follow-up information regarding 1551 persons with a negative 
screening result in a skin cancer-melanoma screening program in 1990. Follow-up was es­
tablished by record linkage with two different population-based registries,
Results: Fifteen persons had new skin cancers. Three of their lesions had been present at the 
original screening and had probably been missed; 12 were genuinely new. N o melanomas were 
among the missed cases. The calculated sensitivity of the screening was 93.3%, its specificity 
was 97.8%, its positive predictive value was 54.0%, and its negative predictive value was 
99.8%.
Conclusion; Visual examination by dermatologists as a screening tool for skin cancer and 
melanoma is appropriate.
(J Am A c a d  D e r m a t o l  1995;33:59-63.)
Screening for skin cancer and melanoma facili­
tates early detection and may reduce morbidity and 
mortality. Visual inspection of the skin by derma­
tologists constitutes a rapid and inexpensive screen­
ing.
The accuracy of visual examination depends on 
the proportion of true-positive, false-positive, true- 
negative, and false-negative results:
True Positives
Sensitivity = True Positives +  False Negatives
Specificity
True Negatives





True Positives -h False Positives
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True Negatives +  False Negatives
False-negative results may be harmful to the pa­
tients screened by causing a false feeling of security 
that may result in undue delays in diagnosis later. 
Ideally, therefore, a test detects only diseased per­
sons and detects all of them. The test should be 
highly sensitive, although a relatively high propor­
tion of false-positive results are acceptable; this es­
pecially relates to skin cancer, because diagnosis and 
treatment of benign skin lesions is easy and inex­
pensive.
The accuracy of skin cancer-melanoma screening 
has not been studied extensively. Some studies have 
examined the positive predictive value of skin can- 
cer-melanoma screening by assessing the true-pos­
itive and false-positive results.1'3 False-negative 
screening résulte derived from follow-up of persons 
with negative findings have never been reported. 
Assessment of the false-negative rate necessitates 
follow-up of all persons with negative screening re­
sults for several years. We studied the occurrence of 
skin malignancies in 1551 persons with negative 
screening results during 42-months of follow-up.
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1 BCC Back NA 36
2 BCC Nose NA 16
3 s e e Lip NA 35
4 s e c Wrist Seborrheic wart 32
5 BCC Forehead Actinic keratosis 41
6 BCC Chin NA 15
7 BCC Nose NA 5
8 BCC Groin NA 17
9 BCC Shoulder NA 22
10 BCC Head NA 2
11 BCC Chest NA 40
12 BCC Back Common nevus 9
13 BCC (4)* Face NA 11-38
14 Melanoma Leg NA 30
15 Melanoma Knee NA 33
BCC, Basal cell carcinoma; N A , no t applicable; SCO, squamous cell carcinoma. 
*Four different lesions.
METHODS
In June 1990 six skin cancer-melanoma screen­
ing programs were conducted in the region of Arn­
hem. The area includes approximately 650,000 per­
sons. The area has seven dermatologists, all of whom 
participated in the study. Practical considerations 
and screening results have been published previous­
ly-3,4
All attending persons were asked to grant per­
mission for evaluation of new skin cancers. Malig­
nancies that were not shown on the participants or 
not recognized as such by the physicians during the 
screenings, but recorded during follow-up, were in­
dicated as new skin cancers. Follow-up of persons 
who had given permission was established by com­
puterized record linkage with two different popula­
tion-based registries: the Regional Cancer Registry 
of the Comprehensive Cancer Center Integraal 
Kankercentrum Oost (IKO), and Pathologisch 
Anatomisch Landelijk Geautomatiseerd Archief 
(PALGA), the Dutch national data base of pathol­
ogy records.
The records of the participants who had given in­
formed consent for follow-up were linked with the 
skin cancer records in both registries for cases diag­
nosed from June 1990 to December 1993. In the first 
stage of the record linkage, records were matched by 
using as identifiers date of birth, sex, and family 
name. In addition, to detect missed matches because 
of incomplete or inaccurate identifiers, various com­
binations of parts of the identifiers were used for 
linkage. The latter procedure was carried out only in 
the linkage with the regional cancer registry. In the 
second stage of the record linkage any false-positive 
matches were distinguished by a check of other 
identifiers such as initials, maiden name, and resi­
dence. This protocol for record linkage has a high 




A total of 1961 persons attended the screenings. 
There were 198 referrals for presumed skin cancer 
(n = 87) or distinct precursor lesions (n — 111). 
Referral was not made for less marked or borderline 
precursor states. Clinical evaluation disclosed 51 
malignancies in 47 persons screened: five melano­
mas, one lentigo maligna, 40 basal cell carcinomas, 
one squamous cell carcinoma, and four cases of 
Bowen’s disease. Additionally, one presumed dys- 
plastic nevus turned out to be a melanoma. All 
malignancies were histopathologically confirmed. 
In addition, several clinically obvious basal cell 
carcinomas diagnosed at one of the clinics were 
treated with cryosurgery without pathologic assess­
ment. These cases, however, were not included in 
the study. Compliance with referral among persons 
with suspected skin cancer was nearly complete 
(93%).
The follow-up efforts concentrated on the 1763
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attendees with negative screening results. Of these, 
1551 (88%) had given written consent to obtain fol­
low-up information. Fifteen persons proved to have 
skin cancer diagnosed during the 42 months of fol- 
low-up. Of these, 14 were linked with both registries. 
One match was reported by the regional cancer reg­
istry only. Table I details these cases. One patient 
had four basal cell carcinomas during follow-up. The 
other cases represent single diagnoses.
Twelve instances were related to frankly new skin 
cancers, not present or discovered during the screens. 
Three patients had skin cancer diagnosed at sites 
that were thought to be normal or benign at the 
original screening. One patient had a basal cell car­
cinoma on his back after 9 months of follow-up. This 
patient attended the screening for a general skin 
check. The records mentioned several common nevi 
on the back. The basal cell carcinoma was probably 
missed at initial presentation. The second patient 
had a squamous cell carcinoma on his wrist, re­
corded as a seborrheic keratosis 32 months previ­
ously. The third had a basal cell carcinoma on the 
forehead. The original diagnosis at screening 41 
months earlier was actinic keratosis.
Three false-negative screening results were found, 
as compared with 1548 true-negative results, among 
the 1551 persons available for follow-up. However, 
to assess the exact rate of true-negative results, the 
number of persons with negative screens who did not 
consent to follow-up (n = 212) must be included. 
The calculated number of false-negative results in 
the total group of negative screening findings is 
1763 -r-1551 X 3 = 3.4. Thus the number of true- 
negative results becomes 1759.6. True-positive re­
sults were obtained in 47 of the 87 cases with 
presumed malignancy. Thus the number of false- 
positive results is 40. From these data the sensitivity 
of our screening exercise was calculated as 
47 t- 50.4 = 0.933 (93.3%). The specificity was 
1759.6 + 1799.6 = 0.978 (97.8%), the positive pre­
dictive value was 47 -r- 87 = 0.54 (54.0%), and the 
negative predictive value was 1759.6 -r 1763 = 
0.998 (99.8%), The persons who were referred for 
distinct precursor lesions (n = 111) are difficult to 
categorize. In a strict sense they have to be regarded 
as having negative screening results. Yet they were 
referred and followed up as those with positive 
screening results. For that reason they have not been 
considered in the assessment of sensitivity, specific­
ity, and predictive values.
The prevalence of skin cancer in this group of
screened persons was 51 of 1961, or 2.6%. In these 
51 persons, 5 5 skin malignancies were detected. The 
cases of skin cancer included 47 true-positive results, 
three false-negative results, and one case of mela­
noma initially classified as a dysplastic nevus. Actu­
ally the true prevalence rate was slightly higher be­
cause several basal cell carcinomas had been treated 
without pathologic confirmation; these tumors were 
not included in the study.
DISCUSSION
Screening for skin cancer and melanoma, al­
though promising, remains a debatable issue.6'10 
One important question about the validity and 
accuracy of the screening test studied, that is, visual 
examination of skin lesions by dermatologists, is its 
sensitivity, specificity, and predictive value.
Most skin cancers diagnosed during follow-up in 
this study in persons with negative screening findings 
were new tumors. Twelve of 15 persons had lesions 
that were not present or that had not been found 
during the screening. Only three lesions actually 
proved to be false-negative lesions, a rate of only 
0.2% of the entire group of 1551 persons with neg­
ative screening findings, followed up for 42 months.
These findings are encouraging. Visual examina­
tion of skin lesions by dermatologists appears to be 
a reliable screening tool. Koh et al.2 estimated the 
sensitivity of skin examination by dermatologists to 
be 97% for melanoma, 94% for basal cell carcinoma, 
and 89% for squamous cell carcinoma. These esti­
mates, however, were not generated from their own 
screening results. Persons with negative screening 
results were not followed. The authors equated the 
false-negative rates with the population incidence 
rates to produce an estimated sensitivity. Our sam­
ple size is not large enough to generate sensitivity 
values for skin cancer subtypes. The overall sensitiv­
ity rate was calculated as 93.3%.
Our results provide the first sensitivity estimates 
for a visual examination performed by dermatolo­
gists in a skin cancer-melanoma screening setting. 
The sensitivity of 93.3% seems to compare favorably 
with sensitivities that have been documented for 
other cancer screening tests, such as fecal occult 
blood test for colon carcinoma (69%), mammogra­
phy for breast cancer (75%), and the Pap smear for 
cervical cancer (78%).2 However, comparison with 
other screening settings is precarious. Among other 
reasons, instituted screening programs are a contin­
uous process and attract incident cases. Our screen­
ing effort was a pilot study in an area without pre­
vious screening for skin cancer and melanoma. 
Therefore the yield of this screening consists of 
prevalent cases.
We included any possible skin cancer in the fol­
low-up period, because this method produces the 
most conservative estimate. We traced three persons 
in whom skin cancer developed 9,32, and 41 months 
after voluntary screening. One had a back lesion, 
initially diagnosed as a nevocellular nevus, that 
turned out to be a basal cell carcinoma after 9 
months. The other false-negative screen results, one 
squamous cell carcinoma and one basal cell carci­
noma, showed a long delay of 32 and 41 months, re­
spectively. It is possible that these two tumors were 
borderline lesions at the time of presentation during 
screening and were difficult or impossible to recog­
nize even by an experienced dermatologist. On the 
other hand, a more thorough search for false-nega­
tive results and/or a longer follow-up period might 
have disclosed additional missed cases.
We did not include in the number of false-nega­
tive screening results the person with a melanoma 
that was misdiagnosed as an atypical nevus. The aim 
of our screening was to detect skin cancer and im­
portant precursor lesions. Persons with atypical nevi 
of high suspicion were given a referral letter to their 
general physician. In this group, although the pre­
sumed diagnosis at screening may be incorrect, a 
suspect lesion will still be properly managed, thereby 
fulfilling the critical function of the screening. Be­
cause the group of 111 persons with referrals for 
precursor lesions is difficult to classify properly, we 
decided to exclude these attendees from analysis. If 
these persons are regarded as having negative screen 
results and if the one melanoma detected in this cat­
egory is regarded as a false-negative finding, then the 
sensitivity of our screening would drop from 93.3% 
to 91.3%.
Other factors may have influenced the low score 
of false-negative findings. Persons may have died 
during the observation period with or from unde­
tected malignancies. Second, within the Arnhem
region it is estimated that migration to other mu­
nicipalities occurs at a rate of 4% to 5% each year. 
Many persons, however, migrate to other munici­
palities within the same area. These do not escape 
detection by the Regional Cancer Registry. Even if 
migration occurs outside the region, the national 
pathology data base (PALGA) would be able to 
trace such instances.
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The potential underreporting of melanoma and 
nonmelanoma skin cancer by pathology laboratories 
and cancer registries may be debatable.1,11 Com­
pleteness of reporting skin malignancies in the area 
under investigation is estimated at around 9 3%.12 
We used two different registries for record linkage. 
This will certainly have reduced the rate of under­
reporting.
The proportion of referrals in this campaign was 
10.1% (198 of 1961). This rate is lower than those 
reported in some American studies.1 ’2 One probable 
reason for the discrepancy is the selective referral 
policy for precursor lesions in our series. To preclude 
unwarranted treatment, only distinct precursor le­
sions were referred. Persons with minimal evidence 
of actinic keratoses, dysplastic nevi, or other inter­
mediate or borderline lesions were not referred.
Dermatologists are able to detect melanomas and 
other skin cancers adequately. The low false-nega­
tive rate and the favorable sensitivity of visual 
inspection of the skin as a screening tool reported in 
this study may lose much of their value when other 
disciplines or paramedical personnel are employed 
during screening. The relative lack of proper recog­
nition of melanoma by nondermatologists is worri­
some.13'15 It has been argued whether screening 
procedures for skin cancer and melanoma should be 
performed by general physicians, nurse clinicians, or 
paraprofessionals. Specifically trained dermatology 
nurses have been employed for (pre)screening, with 
fair agreement rates.1 In general, however, evidence 
favors screening by dermatologists only.
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